Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation

References

• Aggarwal R, Dewan A. 2018. Comparison of nephrotoxicity of colistin with polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 17(1):15. doi: 10.1186/s12941-018-0262-0.
   PubMed Web of Science ®Google Scholar
• Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis. 57(9):1300–1303. doi: 10.1093/cid/cit453.
   PubMed Web of Science ®Google Scholar
• Avedissian SN, Liu J, Rhodes NJ, Lee A, Pais GM, Hauser AR, Scheetz MH. 2019. A review of the clinical pharmacokinetics of polymyxin B. Antibiotics (Basel). 8(1):31. doi: 10.3390/antibiotics8010031.
   PubMed Web of Science ®Google Scholar
• Avedissian SN, Miglis C, Kubin CJ, Rhodes NJ, Yin MT, Cremers S, Prickett M, Scheetz MH. 2018. Polymyxin B pharmacokinetics in adult cystic fibrosis patients. Pharmacotherapy. 38(7):730–738. doi: 10.1002/phar.2129.
   PubMed Web of Science ®Google Scholar
• Begg EJ, Barclay ML, Duffull SB. 1995. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 39(6):605–609. doi: 10.1111/j.1365-2125.1995.tb05719.x.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, Li J. 2012. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn Microbiol Infect Dis. 74(3):213–223. doi: 10.1016/j.diagmicrobio.2012.07.010.
   PubMed Web of Science ®Google Scholar
• Bian X, Liu X, Hu F, Feng M, Chen Y, Bergen PJ, Li J, Li X, Guo Y, Zhang J. 2021. Pharmacokinetic/pharmacodynamic based breakpoints of polymyxin B for bloodstream infections caused by multidrug-resistant gram-negative pathogens. Front Pharmacol. 12:785893. doi: 10.3389/fphar.2021.785893.
   PubMed Web of Science ®Google Scholar
• Chen W, Liu H, Wang Q, Wang X, Kong X, Wang X, Zhang X, Zhan Q, Li P. 2021. Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese patients with severe pneumonia. Eur J Clin Pharmacol. 77(1):95–105. doi: 10.1007/s00228-020-02986-x.
   PubMed Web of Science ®Google Scholar
• Flannery AH, Delozier NL, Effoe SA, Wallace KL, Cook AM, Burgess DS. 2020. First-dose vancomycin pharmacokinetics versus empiric dosing on area-under-the-curve target attainment in critically ill patients. Pharmacotherapy. 40(12):1210–1218. doi: 10.1002/phar.2486.
   PubMed Web of Science ®Google Scholar
• Hanafin PO, Nation RL, Scheetz MH, Zavascki AP, Sandri AM, Kwa AL, Cherng BPZ, Kubin CJ, Yin MT, Wang J, et al. 2021. Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT Pharmacomet Syst Pharmacol. 10(12):1525–1537. doi: 10.1002/psp4.12720.
   PubMedGoogle Scholar
• Kubin CJ, Nelson BC, Miglis C, Scheetz MH, Rhodes NJ, Avedissian SN, Cremers S, Yin MT. 2018. Population pharmacokinetics of intravenous polymyxin B from clinical samples. Antimicrob Agents Chemother. 62(3):e01493–01417. doi: 10.1128/AAC.01493-17.
   PubMed Web of Science ®Google Scholar
• Kwa A, Kasiakou SK, Tam VH, Falagas ME. 2007. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 5(5):811–821. doi: 10.1586/14787210.5.5.811.
   PubMed Web of Science ®Google Scholar
• Kwa AL, Abdelraouf K, Low JG, Tam VH. 2011. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 52(10):1280–1281. doi: 10.1093/cid/cir137.
   PubMed Web of Science ®Google Scholar
• Kwa AL, Lim TP, Low JG, Hou J, Kurup A, Prince RA, Tam VH. 2008. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 60(2):163–167. doi: 10.1016/j.diagmicrobio.2007.08.008.
   PubMed Web of Science ®Google Scholar
• Lakota EA, Landersdorfer CB, Nation RL, Li J, Kaye KS, Rao GG, Forrest A. 2018. Personalizing polymyxin B dosing using an adaptive feedback control algorithm. Antimicrob Agents Chemother. 62(7):e00483–00418. doi: 10.1128/AAC.00483-18.
   PubMed Web of Science ®Google Scholar
• Landersdorfer CB, Wang J, Wirth V, Chen K, Kaye KS, Tsuji BT, Li J, Nation RL. 2018. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models. J Antimicrob Chemother. 73(2):462–468. doi: 10.1093/jac/dkx409.
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 6(9):589–601. doi: 10.1016/S1473-3099(06)70580-1.
   PubMed Web of Science ®Google Scholar
• Li Y, Deng Y, Zhu ZY, Liu YP, Xu P, Li X, Xie YL, Yao HC, Yang L, Zhang BK, et al. 2021. Population pharmacokinetics of polymyxin B and dosage optimization in renal transplant patients. Front Pharmacol. 12:727170. doi: 10.3389/fphar.2021.727170.
   PubMed Web of Science ®Google Scholar
• Liu Q, Huang H, Xu B, Li D, Liu M, Shaik IH, Wu X. 2022. Two innovative approaches to optimize vancomycin dosing using estimated AUC after first dose: validation using data generated from population PK model coupled with Monte-Carlo simulation and comparison with the first-order PK equation approach. Pharmaceutics. 14(5):1004. doi: 10.3390/pharmaceutics14051004.
   PubMed Web of Science ®Google Scholar
• Liu X, Chen Y, Yang H, Li J, Yu J, Yu Z, Cao G, Wu X, Wang Y, Wu H, et al. 2021. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: a safety and pharmacokinetic study in healthy Chinese subjects. J Infect. 82(2):207–215. doi: 10.1016/j.jinf.2021.01.006.
   PubMed Web of Science ®Google Scholar
• Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic JT, Lye DC, Lee LS, Tam VH. 2018. Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther. 104(3):534–538. doi: 10.1002/cpt.981.
   PubMed Web of Science ®Google Scholar
• Matzke GR, Zhanel GG, Guay DR. 1986. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 11(4):257–282. doi: 10.2165/00003088-198611040-00001.
   PubMed Web of Science ®Google Scholar
• Miglis C, Rhodes NJ, Avedissian SN, Kubin CJ, Yin MT, Nelson BC, Pai MP, Scheetz MH. 2018. Population pharmacokinetics of polymyxin B in acutely ill adult patients. Antimicrob Agents Chemother. 62(3):e01475–01417. doi: 10.1128/AAC.01475-17.
   PubMed Web of Science ®Google Scholar
• Nang SC, Azad MAK, Velkov T, Zhou QT, Li J. 2021. Rescuing the last-line polymyxins: achievements and challenges. Pharmacol Rev. 73(2):679–728. doi: 10.1124/pharmrev.120.000020.
   PubMed Web of Science ®Google Scholar
• Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, et al. 2015. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 15(2):225–234. doi: 10.1016/S1473-3099(14)70850-3.
   PubMed Web of Science ®Google Scholar
• Nation RL, Rigatto MHP, Falci DR, Zavascki AP. 2019. Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity. Antibiotics (Basel)). 8(1):24. doi: 10.3390/antibiotics8010024.
   PubMed Web of Science ®Google Scholar
• Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 59(1):88–94. doi: 10.1093/cid/ciu213.
   PubMed Web of Science ®Google Scholar
• Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 58(5):2740–2746. doi: 10.1128/AAC.02476-13.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Oliveira MS, Perdigão-Neto LV, Levin AS, Carrilho CM, Tanita MT, Tuon FF, Cardoso DE, Lopes NT, Falci DR, et al. 2016. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 60(4):2443–2449. doi: 10.1128/AAC.02634-15.
   PubMed Web of Science ®Google Scholar
• Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, et al. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 57(4):524–531. doi: 10.1093/cid/cit334.
   PubMed Web of Science ®Google Scholar
• Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Saitovitch D, Wang J, Forrest A, et al. 2012. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother. 68(3):674–677. doi: 10.1093/jac/dks437.
   PubMed Web of Science ®Google Scholar
• Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. 2005. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 49(9):3624–3630. doi: 10.1128/AAC.49.9.3624-3630.2005.
   PubMed Web of Science ®Google Scholar
• Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, Tam VH. 2017. Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency. Antimicrob Agents Chemother. 61(1):e01337–01316. doi: 10.1128/AAC.01337-16.
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Landersdorfer CB, Lenhard JR, Cheah SE, Thamlikitkul V, Rao GG, Holden PN, Forrest A, Bulitta JB, Nation RL, et al. 2016. Paradoxical effect of polymyxin B: high drug exposure amplifies resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 60(7):3913–3920. doi: 10.1128/AAC.02831-15.
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, et al. 2019. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 39(1):10–39. doi: 10.1002/phar.2209.
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. 2014. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 43(4):349–352. doi: 10.1016/j.ijantimicag.2013.12.002.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang Q, Feng M, Sun T, Yang J, Zhang X. 2021. Population pharmacokinetics of polymyxin B in obese patients for resistant gram-negative infections. Front Pharmacol. 12:754844. doi: 10.3389/fphar.2021.754844.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang Q, Zhu Z, Feng M, Sun T, Yang J, Zhang X. 2020. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections. Front Pharmacol. 11:829. doi: 10.3389/fphar.2020.00829.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang Q, Zhu Z, Pei H, Feng M, Sun T, Yang J, Zhang X. 2021. Comparing the population pharmacokinetics of and acute kidney injury due to polymyxin B in Chinese patients with or without renal insufficiency. Antimicrob Agents Chemother. 65(2):e01900–01920. doi: 10.1128/AAC.01900-20.
   PubMed Web of Science ®Google Scholar
• Yu XB, Jiao Z, Zhang CH, Dai Y, Zhou ZY, Han L, Wen X, Sheng CC, Lin GY, Pan JY. 2021. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions. Br J Clin Pharmacol. 87(4):1869–1877. doi: 10.1111/bcp.14576.
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 60(6):1206–1215. doi: 10.1093/jac/dkm357.
   PubMed Web of Science ®Google Scholar